TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
VistaGen Therapeutics ( (VTGN) ) has issued an announcement.
VistaGen Therapeutics announced the resignation of its Chief Financial Officer, Cynthia L. Anderson, effective October 15, 2025. The company is searching for her successor and plans to retain her as a consultant to ensure a smooth transition. Additionally, at the 2025 Annual Meeting of Stockholders held on September 9, 2025, VistaGen’s stockholders elected six directors to the Board, approved executive compensation, and ratified KPMG LLP as the independent auditor for the fiscal year ending March 31, 2026.
The most recent analyst rating on (VTGN) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.
Spark’s Take on VTGN Stock
According to Spark, TipRanks’ AI Analyst, VTGN is a Neutral.
VistaGen Therapeutics shows potential with strong technical momentum and promising clinical advancements. However, financial performance remains a significant concern due to ongoing losses and negative cash flow. The company’s valuation is impacted by its development stage, reflected in a negative P/E ratio. The earnings call provided positive guidance on clinical progress, but operational challenges persist. Corporate events, while positive, are not weighted in the final score.
To see Spark’s full report on VTGN stock, click here.
More about VistaGen Therapeutics
Average Trading Volume: 452,441
Technical Sentiment Signal: Buy
Current Market Cap: $104M
For an in-depth examination of VTGN stock, go to TipRanks’ Overview page.